Literature DB >> 7890687

The fibronectin-binding domain of transglutaminase.

J M Jeong1, S N Murthy, J T Radek, L Lorand.   

Abstract

Guinea pig liver transglutaminase (EC 2.3.2.13) displays a Ca(2+)-independent binding (Ka = 10(7) M-1) to the same gelatin-binding domain of human plasma fibronectin that is known to form a very tight complex with the human red cell enzyme. The fibronectin-combining site of the liver transglutaminase was investigated by testing fragments obtained from the parent protein by controlled digestion with endoproteinase Lys-C. Overlay assays, probed with anti-fibronectin antibody, revealed that the fibronectin binding ability of the transglutaminase was encoded in a linear sequence in its 28-kDa N-terminal domain. Removal of the first 7 residues by further digestion of the purified 28-kDa material with endoproteinase Glu-C generated a 27-kDa fragment that, however, showed no binding activity. Thus, residues 1-7 in the liver enzyme seem to be of particular importance for influencing its ability to bind to fibronectin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890687     DOI: 10.1074/jbc.270.10.5654

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Reactivity of the N-terminal region of fibronectin protein to transglutaminase 2 and factor XIIIA.

Authors:  Brian R Hoffmann; Douglas S Annis; Deane F Mosher
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

2.  Hierarchies in the binding of human factor XIII, factor XIIIa, and endothelial cell transglutaminase to human plasma fibrinogen, fibrin, and fibronectin.

Authors:  K E Achyuthan; T C Rowland; P J Birckbichler; K N Lee; P D Bishop; A M Achyuthan
Journal:  Mol Cell Biochem       Date:  1996-09-06       Impact factor: 3.396

3.  The role of transglutaminase in the rat subtotal nephrectomy model of renal fibrosis.

Authors:  T S Johnson; M Griffin; G L Thomas; J Skill; A Cox; B Yang; B Nicholas; P J Birckbichler; C Muchaneta-Kubara; A Meguid El Nahas
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

4.  Autoantibodies from patients with coeliac disease recognize distinct functional domains of the autoantigen tissue transglutaminase.

Authors:  J Seissler; U Wohlrab; C Wuensche; W A Scherbaum; B O Boehm
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

5.  Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity.

Authors:  S N Prasanna Murthy; Siiri Iismaa; Gillian Begg; Douglas M Freymann; Robert M Graham; Laszlo Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

6.  Interactions of G(h)/transglutaminase with phospholipase Cdelta1 and with GTP.

Authors:  S N Murthy; J W Lomasney; E C Mak; L Lorand
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

7.  EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation.

Authors:  Bo Li; Marc A Antonyak; Joseph E Druso; Le Cheng; Alexander Yu Nikitin; Richard A Cerione
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

8.  Association of a transglutaminase-related antigen with intermediate filaments.

Authors:  A V Trejo-Skalli; P T Velasco; S N Murthy; L Lorand; R D Goldman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-09-12       Impact factor: 11.205

9.  Activity-regulating structural changes and autoantibody epitopes in transglutaminase 2 assessed by hydrogen/deuterium exchange.

Authors:  Rasmus Iversen; Simon Mysling; Kathrin Hnida; Thomas J D Jørgensen; Ludvig M Sollid
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

10.  Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.

Authors:  Rasmus Iversen; Roberto Di Niro; Jorunn Stamnaes; Knut E A Lundin; Patrick C Wilson; Ludvig M Sollid
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.